Compare Goodyear Tire & Rubber Co (GT) vs Tango Therapeutics Inc. (TNGX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Goodyear Tire & Rubber Co vs Tango Therapeutics Inc. — how do they compare? Goodyear Tire & Rubber Co trades at $4.39 (market cap $1.31B), while Tango Therapeutics Inc. trades at $22.23 (market cap $3.75B). The key difference: Tango Therapeutics Inc. is far larger — about 2.9× Goodyear Tire & Rubber Co's market cap, and Tango Therapeutics Inc. is trading nearer its 52-week high, Goodyear Tire & Rubber Co nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Goodyear Tire & Rubber Co for 58 Days and Tango Therapeutics Inc. for 0 Days on average.
| GT | TNGX | |
|---|---|---|
Market Cap | $1.31B | $3.75B |
Volume | 8,331,802 | 9,619,106 |
Sector | Consumer Cyclical | Health |
52-Week High | $10.54 | $32.90 |
52-Week Low | $4.38 | $7.50 |
Typical Hold Time | 58 Days | 0 Days |
Enterprise Value | $8.66B | $2.77B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
The Goodyear Tire & Rubber Company (GT) trades at $4.38, down 2.45% on the day, reflecting persistent bearish technical momentum. The stock shows deeply discounted valuation ratios, including a P/E of 4.69 and P/B of 0.46, but faces significant fundamental challenges with a net income margin of -14.37% and negative ROE of -63.93% for 2025. Recent earnings have been mixed, with Q2 2026 beating expectations but still posting a loss. Cash flow trends show modest improvement, with net cash flow turning positive in 2025 and 2026. Analyst sentiment is mixed, with a consensus price target of $8.00 implying substantial upside, though technical indicators remain bearish overall.
Outlook: GT presents a high-risk, high-reward opportunity. The stock is fundamentally undervalued, and successful execution of its restructuring and margin expansion strategy could drive significant appreciation toward the analyst target. However, persistent losses, high debt, and competitive pressures pose substantial risks. Investors should weigh the potential for a turnaround against the company's current financial instability and bearish market sentiment.
TNGX trades at $22.22, down 8.07% in the last session, reflecting negative investor reaction to recent earnings misses. The stock shows neutral technical signals with key support at $21 and resistance at $23. Fundamentally, the company maintains a high gross margin of 98.25% but faces significant losses with a net income margin of -229.92% and negative cash flow from operations. Recent news highlights institutional buying interest and upcoming clinical trial developments.
Despite strong analyst support with a $45.91 consensus price target (107% upside), TNGX faces substantial execution risks as a clinical-stage biotech. The company's heavy cash burn and lack of profitability require careful monitoring of pipeline progress. Investment appeal hinges on successful drug development outcomes rather than current financial metrics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Goodyear Tire & Rubber Co
Goodyear Tire & Rubber Co manufactures and sells a variety of rubber tires under the Goodyear brand name. The firm's tires are used for automobiles, trucks, buses, aircraft, motorcycles, mining equipment, farm equipment, and industrial equipment.
Read more on GT →About Tango Therapeutics Inc.
Tango Therapeutics, Inc. is a clinical-stage biotechnology company focused on precision oncology, developing cancer therapies based on the genetic principle of synthetic lethality, including its PRMT5 inhibitor program.
Read more on TNGX →
